Tag: European patent
Company News: ISA Pharmaceuticals Granted European Patent for the Intradermal Administration of ISA101
– Intradermal administration provides significant benefits compared to subcutaneous application
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has been granted a European patent (patent no. EP 2 155 240) for the intradermal administration of synthetic long peptides (SLP®s) based on HPV oncogenes, including its lead compound ISA101.
Specifically, the patent was granted for the therapeutic use of intradermally delivered long peptides derived from the E2, E6 and/or E7 proteins of the human papillomavirus (HPV) to treat or prevent HPV-related diseases.
ISA101 is a clinical-stage immunotherapeutic for the treatment of early-stage, advanced and recurrent cancers induced by HPV16 infections and is based on ISA Pharmaceuticals´ proprietary SLP® platform. The compound is currently in clinical Phase I/II trials in cervical cancer and anal intraepithelial neoplasia (AIN).
As shown in healthy volunteers, intradermal administration of low doses of the HPV16 E6 and E7 SLP® without any adjuvant resulted in an effective, long-lasting systemic T cell response. This shows that, compared to subcutaneous delivery, the new epidermal routing with lower doses and absence of a concomitant adjuvant is also capable of eliciting a robust immune response in naïve individuals.
Company News: Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies
– Invention provides unique technology base for therapeutic human bispecific antibodies
– Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes
Merus B.V., a biopharmaceutical company focusing on innovative antibody therapeutics, today announced that it has been granted a European patent on its MeMo® transgenic mouse for the generation of common light chain human antibodies. Using standard industry processes, MeMo®-derived common light chain antibodies can be manufactured in clonal cell lines to efficiently obtain full-length IgG human bispecific antibodies (branded as Biclonics™) for therapy.
“We are very pleased about this important patent as it underlines our unique approach to creating improved antibody therapeutics,” said Ton Logtenberg, CEO of Merus. “MeMo® is distinct from other transgenic mice for human antibodies because the common light chain facilitates co-expression of two antibodies in a single cell to generate functional bispecific antibodies. By screening thousands of bispecific antibodies in cell-based assays, antibody therapeutics with truly superior functional activities are efficiently identified. The full-length IgG format provides for using established, ‘off-the-shelve’ analytical and manufacturing processes which are already in place for therapeutic monoclonal antibodies.”
“This is a major accomplishment of Merus,” said Jason Avery, CBO of Merus. “The company has built an exceptional product and technology base for superior therapeutics that combine the benefits of full-length IgG monoclonal antibodies with the ability of simultaneously addressing multiple disease targets. MeMo® is a source of large panels of high quality human antibodies that may be used to rapidly identify bispecific antibody leads. We are offering biopharmaceutical companies worldwide a non-exclusive license to MeMo®. There are no target restrictions and license terms are flexible.”